Nina Ni1, Muthiah Srinivasan, Stephen D McLeod, Nisha R Acharya, Thomas M Lietman, Jennifer Rose-Nussbaumer. 1. aFrancis I. Proctor Foundation bDepartment of Ophthalmology, University of California San Francisco, San Francisco, California, USA cAravind Eye Hospital, Madurai, India dDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Abstract
PURPOSE OF REVIEW: Topical corticosteroid use in the setting of infectious keratitis has been a controversial issue. The aim of this review is to provide an update on the evidence for use of topical corticosteroids in addition to antibiotics in bacterial keratitis. RECENT FINDINGS: Judicious use of steroids is postulated to limit the inflammatory component of bacterial keratitis, but can theoretically retard healing. Three small randomized controlled trials and one large-scale trial, the Steroids for Corneal Ulcers Trial, have provided the most recent evidence to address this debate. Adjunctive topical corticosteroids initiated after at least 48 h of antibiotic usage in cases of culture-proven bacterial keratitis appear generally safe in the treatment of bacterial keratitis. They may be beneficial in cases of severe ulcers especially when initiated early in the course of the infection, in non-Nocardia ulcers, and in certain Pseudomonas ulcers. SUMMARY: Several randomized controlled trials have greatly contributed to our understanding of the controversy over steroid use in the management of bacterial keratitis. Future studies are needed to confirm subgroup analysis findings and define optimal timing, dosage, and the most appropriate treatment populations.
PURPOSE OF REVIEW: Topical corticosteroid use in the setting of infectious keratitis has been a controversial issue. The aim of this review is to provide an update on the evidence for use of topical corticosteroids in addition to antibiotics in bacterial keratitis. RECENT FINDINGS: Judicious use of steroids is postulated to limit the inflammatory component of bacterial keratitis, but can theoretically retard healing. Three small randomized controlled trials and one large-scale trial, the Steroids for Corneal Ulcers Trial, have provided the most recent evidence to address this debate. Adjunctive topical corticosteroids initiated after at least 48 h of antibiotic usage in cases of culture-proven bacterial keratitis appear generally safe in the treatment of bacterial keratitis. They may be beneficial in cases of severe ulcers especially when initiated early in the course of the infection, in non-Nocardia ulcers, and in certain Pseudomonasulcers. SUMMARY: Several randomized controlled trials have greatly contributed to our understanding of the controversy over steroid use in the management of bacterial keratitis. Future studies are needed to confirm subgroup analysis findings and define optimal timing, dosage, and the most appropriate treatment populations.
Authors: Fiona Stapleton; Lisa J Keay; Paul G Sanfilippo; Suchi Katiyar; Katie P Edwards; Thomas Naduvilath Journal: Am J Ophthalmol Date: 2007-08-29 Impact factor: 5.258
Authors: Lisa Keay; Katie Edwards; Thomas Naduvilath; Hugh R Taylor; Grant R Snibson; Kevin Forde; Fiona Stapleton Journal: Ophthalmology Date: 2005-12-19 Impact factor: 12.079
Authors: Kathryn J Ray; Muthiah Srinivasan; Jeena Mascarenhas; Revathi Rajaraman; Meenakshi Ravindran; David V Glidden; Catherine E Oldenburg; Catherine Q Sun; Michael E Zegans; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman Journal: JAMA Ophthalmol Date: 2014-06 Impact factor: 7.389
Authors: Aileen Sy; Muthiah Srinivasan; Jeena Mascarenhas; Prajna Lalitha; Revathi Rajaraman; Meenakshi Ravindran; Catherine E Oldenburg; Kathryn J Ray; David Glidden; Michael E Zegans; Stephen D McLeod; Thomas M Lietman; Nisha R Acharya Journal: Invest Ophthalmol Vis Sci Date: 2012-01-25 Impact factor: 4.799
Authors: Sumayya Ahmad; Michelle Lopez; Marwan Attala; Anat Galor; Natalie A Stanciu; Darlene Miller; Leejee Suh; Thomas Albini; Victor L Perez; Carol L Karp; Janet L Davis; Eduardo Alfonso; Richard K Forster; Guillermo Amescua Journal: Ocul Immunol Inflamm Date: 2017-10-17 Impact factor: 3.070